Red Clover Extract for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Red Clover Extract for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A standardized plant extract acting on estrogen receptors, favoring bone, blood vessels and brain over breast and uterus. Its clearest effect is fewer heat surges in the menopausal transition, mainly at higher doses, frequent symptoms and particular extract chemistry. Blood fats, artery elasticity and spine bone loss improve less consistently. Side effects match dummy treatment. Products vary in strength. (Full Review)

Protocol

Standard dose
40–80 mg isoflavones daily
The range used in essentially all controlled trials; the hot flash effect is concentrated at 80 mg daily.
Single versus split dosing
40 mg twice daily
The schedule used in the trials showing lipid and symptom benefit; evening dosing is preferred where night sweats dominate.
Extract selection
Promensil or Menoflavon
The most-studied standardized extract, roughly 50% biochanin A and 35% formononetin; Menoflavon is considered equivalent.
Time to effect
Vasomotor improvement
4–12 weeks
Pooled analyses show the clearest separation from placebo at twelve weeks.
Lipid changes
3 months
Total and LDL cholesterol reductions are measurable by the first three-month lipid recheck.
Bone effects
12 months
The trials showing attenuated lumbar spine loss tracked bone density over twelve months.

Benefits

Contraindications
  • Pregnancy and lactation, at any dose
  • Active or prior estrogen-receptor-positive breast cancer, and endometrial cancer, unless supervised by the treating oncologist
  • Endocrine cancer therapy (tamoxifen, anastrozole, letrozole, exemestane, fulvestrant) outside oncology supervision
  • Undiagnosed vaginal or postmenopausal bleeding, until the cause has been established
  • Inherited or acquired bleeding disorders, and anticoagulation with an unstable international normalized ratio
  • Surgery or a neuraxial procedure scheduled within 14 days
  • Active liver disease or transaminases above three times the upper limit of normal
  • Children and adolescents under 18 years
  • Men under active prostate cancer surveillance who rely on serial prostate-specific antigen measurements
Key Interactions
  • Anticoagulants and antiplatelets (warfarin, apixaban, rivaroxaban, clopidogrel, low-dose aspirin)
  • Over-the-counter analgesics and supplements affecting platelets (ibuprofen, naproxen, aspirin, fish oil, ginkgo, garlic, high-dose vitamin E, nattokinase)
  • Methotrexate
  • Menopausal hormone therapy (estradiol, conjugated equine estrogens, oral contraceptives)
  • Levothyroxine and thyroid hormone replacement
  • Drug transporter substrates (digoxin, rosuvastatin)
  • Drugs cleared by cytochrome P450 enzymes (caffeine, tolbutamide, dextromethorphan, alprazolam): low concern
  • Other phytoestrogen supplements (soy isoflavones, kudzu, hops, flaxseed lignans, dong quai, black cohosh)

Risk & Side Effects

  • High: Mild adverse events at placebo-equivalent rates
    •
  • Medium: Estrogenic stimulation of breast and endometrial tissue, conflicted; unpredictable isoflavone exposure from variable products
  • Low: Elevated liver transaminases; suppression of serum prostate-specific antigen in men; bleeding and coagulation disturbance
  • Speculative: Interference with methotrexate elimination; thyroid hormone interference

Monitoring

Marker Target Why
Total cholesterol 160–200 mg/dL Primary lipid endpoint with pooled trial support
LDL cholesterol < 100 mg/dL, < 70 mg/dL with cardiovascular disease Tracks the fraction most reduced by biochanin-rich extract
HDL cholesterol > 60 mg/dL women, > 50 mg/dL men Small favorable shift reported in pooled analyses
Triglycerides < 100 mg/dL Improved in perimenopausal participants specifically
Alanine aminotransferase (ALT) < 25 U/L women, < 30 U/L men Detects the transaminase rise reported at 60 mg daily
Thyroid-stimulating hormone (TSH) 0.5–2.5 mIU/L Isoflavones can inhibit thyroid hormone synthesis
C-terminal telopeptide (CTX) Lower half of the premenopausal reference range Earliest signal of the bone turnover effect
Lumbar spine and femoral neck bone density T-score above −1.0, or no annual loss The endpoint two trials moved and one did not
Endometrial thickness < 5 mm postmenopausal Addresses the unresolved proliferation question
Prostate-specific antigen (PSA) < 4 ng/mL, and stable against the individual's own baseline The extract can lower it by a third and mask a rising trend
International normalized ratio (INR) 2.0–3.0 if anticoagulated, otherwise near 1.0 Coumarin content and two bleeding case reports
Urinary or serum equol No established target; determine producer status once Non-producers convert far less daidzein to the potent metabolite

Cadence: Baseline set before starting; liver transaminases and the symptom count at twelve weeks; lipids at three and six months; thyroid function, bone density and endometrial status every twelve months, or sooner if bleeding occurs.

Qualitative Assessment

  • Daily count and severity rating of hot flashes and night sweats, recorded the same way before and during use
  • Number of night awakenings attributable to sweating, and subjective sleep quality on waking
  • Vaginal comfort and dryness, and any change in urinary urgency
  • Mood stability, irritability and anxiety over the preceding week
  • Energy through the afternoon, and cognitive clarity during demanding tasks
  • Any bruising, gum bleeding or unusually heavy bleeding, which would prompt immediate reassessment
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.